key: cord-0905095-wjkekuoo authors: Apaydin, Hakan; Can Güven, Serdar; Doğan, İsmail; Çolak, Aysel; Süngü, Nuran; Erten, Şükran title: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis presented as pulmonary-renal syndrome in a coronavirus disease-2019 (COVID-19) patient date: 2021-09-25 journal: The Egyptian Rheumatologist DOI: 10.1016/j.ejr.2021.08.011 sha: 676f1058775e6d3211bd371949349e7f1c9eb9e7 doc_id: 905095 cord_uid: wjkekuoo Introduction Coronavirus disease 2019 (COVID-19) is a global pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The SARS-CoV-2 virus primarily targets the respiratory system, but extrapulmonary involvement can be frequently seen. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is systemic autoimmune disease that may lead to renal failure due to the infiltration of mononuclear cells and the destruction of small- and medium-sized blood vessels. It has been shown that SARS-CoV-2 infection may trigger the presentation or exacerbation of autoimmune diseases. Case report: A case of AAV, manifesting as diffuse alveolar hemorrhage and rapidly progressive kidney disease after COVID-19 infection has been presented. At presentation, the patient had rapidly progressive kidney disease and active urinary sediment; chest computerized tomography (CT) findings primarily suggested alveolar hemorrhage with a positive serum proteinase 3-ANCA (PR3-ANCA) test. The patient was considered as AAV associated pulmonary-renal syndrome possibly triggered by COVID-19 infection. The patient received pulse corticosteroids, plasma exchange and intravenous immunoglobulin as treatment. Mycophenolate mofetil was added as an immunosuppressive therapy. After 6 months, kidney functions completely recovered. Conclusion: This case highlights that SARS-CoV-2 disease could be the trigger for AAV, and this should be kept in mind in such cases. Early detection of AAV is important in cases infected or co-infected with COVID-19, and prompt diagnosis and appropriate management of AAV-associated pulmonary-renal syndrome are essential to reduce the morbidity and mortality. Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people and caused thousands of deaths. SARS-CoV-2 is known to cause significant pulmonary diseases, including pneumonia and acute respiratory distress syndrome (ARDS), and may also present with diffuse alveolar hemorrhage (DAH) [1] . DAH can complicate many clinical situations and can be life-threatening, requiring immediate treatment. Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), primarily affects small and medium-sized arteries. GPA mainly affects the upper respiratory system tract, lungs and kidneys, and patients with lung involvement may present with alveolar hemorrhage, and these patients have a significant risk of mortality due to respiratory failure. Clinical signs, ANCA serology, and histology of the affected organ are used to diagnose AAV [2] . Various extrapulmonary manifestations of COVID-19 have been reported. Acute kidney injury (AKI) is commonly reported in the COVID-19 course [3] . Renal involvement is one of the major organ involvements also in AAV. COVID-19 and AAV share many similar clinical and radiological features, making it difficult for clinicians to diagnose [4] . Infectious diseases are a known cause of AAV; however, the relation with COVID- 19 has not yet been clarified. Herein, a case of AAV presented with rapidly progressive renal failure and alveolar hemorrha ge during the course of COVID-19 has been reported. An 18-year-old male patient without any remarkable medical history was admitted to the emergency department on September 7 th , 2020 with fever, cough, and malaise. On admission, the patient was conscious and cooperative, with a blood pressure 124/54 mmHg, heart rate 98 beats/minute, body temperature 37°C, and respiratory rate 20/minute. Oxygen saturation in room air was 94%. The laboratory results were as follows: hemoglobin 14.1 g/dL (12.2-18.1), platelet and white blood cell (WBC) count were normal, lymphocyte count 660 (1100-4500), creatinine 0.96 mg/dL (0.67-1.17), C-reactive protein (CRP) 86 mg/dL (0-5), liver function tests, cardiac enzymes, ferritin, procalcitonin, and coagulation parameters were normal. Serum immunoglobulin levels were within normal ranges. The case management was approved and in accordance to the local ethical standards and the patient consent was attained. The patient was diagnosed as COVID-19 with a positive nasopharyngeal SARS-CoV-2 polymerase chain reaction (PCR) test. The patient was then hospitalized, and was prescribed favipira vir, hydroxychloroquine (HCQ), and low-molecular-weight heparin (LMWH). Following day, the patient developed hemoptysis of 30-40 cc at a time with a total bleeding of 2-3 cups. O2 saturation was 95% with 2 L/min nasal oxygen. Repeat laboratory evaluation revealed decreased hemoglobin (8.1 g/dL) and elevated serum creatinine (1.2 mg/dL). In the urinalysis, 140 erythrocytes and 5 leukocytes were detected. The spot urine protein/creatinine ratio revealed a protein excretion of 987 mg/day. In the urine sediment, abundant isomorphic erythrocytes, granular and leukocyte casts were observed. Computed tomography (CT) chest revealed fused consolidation and infiltrations in the form of ground-glass opacity in both lungs, especially the left. This was interpreted primarily in favor of diffuse alveolar hemorrhage (DAH) (Figure 1 ). The patient was then admitted to the intensive care unit (ICU) and LMWH treatment stopped. The serum creatinine level further increased to 1.86 mg/dL and O2 saturation dropped to 82%, requiring high-flow oxygen therapy. Further laboratory tests were negative for anti-nuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA), antiextractable nuclear antigens and anti-glomerular basal membrane antibodies, but positive for proteinase 3 (PR3)-ANCA by indirect immunofluorescence assay (1/320 titer) and enzyme -linked immunosorbent assay (ELISA) (> 200 RU/mL). Serum complement levels were normal. The rheumatology department was then consulted. The patient had rapidly progressive kidney disease and active urinary sediment, chest CT suggestive of DAH and a positive PR3-ANCA ELISA test. Accordingly, the patient was considered as AAVassociated pulmonary-renal syndrome possibly triggered by COVID-19 infection. Goodpasture's syndrome, systemic lupus erythematosus (SLE), cryoglobulinemia, rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease, polymyositis and dermatomyositis, infectio ns, malignancies, antiphospholipid syndrome, environmental factors and drugs were excluded as the differential diagnosis of conditions causing pulmonary-renal syndrome. Pulse methylprednisolone 1 g/day for three days was initiated, followed by 60 mg/d, and plasma exchange was performed every day for seven courses followed by intravenous immunoglobulin (IVIG) therapy (0.4 g/kg/d) for five days. The favipiravir and HCQ regiments were simultaneously completed for five days. Pulmonar y findings rapidly regressed, hemoptysis did not recur, the patient was no more O2-dependent, and CRP levels lowered to the normal range. A significant regression was observed on chest radiography ( Figure 2 ). However, the serum creatinine level continued to progress, reaching over 3 mg/dL. With three consecutive negative COVID-19 PCR tests, patient was transferred to the rheumato lo gy clinic after nine days of ICU stay. A kidney biopsy was scheduled due to the persistent elevation in the serum creatinine level. A tru-cut biopsy was performed from the lower pole of the right kidney revealing fibrocellular crescent in one glomerule, an early stage of cellular crescent morphology in a second glomerule and segmental sclerosis in another. Fibrinoid necrosis accompanied crescentic glomeruli. In some other glomeruli, mild mesangial cellular proliferation and an increase in the thickness of the basement membranes in one glomerule were noted. In the immunofluoresce nce examination, focal, mesangial coarse granular staining with IgA, IgM and C3 complement was observed ( Figure 3 ). During the follow-up of the patient, the serum creatinine level increased to 1.15 mg/dl. Methylprednisolone 60 mg/d was planned to be continued for one month, and to be tapered gradually thereafter. The patient did not accept rituximab or cyclophosphamide treatments, which were considered as remission induction therapy, due to possible side effects. Mycophenolate mofetil 2 g/day was added to the treatment as a steroid-sparing agent. The patient was discharged after a total of 42-day hospital stay. In the 6 th -month follow-up, patient was under 8 mg/day methylpredniso lo ne and 2 g/day mycophenolate mofetil. PR3-ANCA ELISA was still elevated yet the creatinine value was 0.79 mg/dL, CRP level was within normal range and patient was symptom free, therefore accepted to be in remission. Herein, an 18-year-old male COVID-19 patient presented with DAH and acute renal failure diagnosed as AAV has been described. There is growing evidence of extrapulmonary manifestations of COVID- 19 . In the United States, the incidence of acute kidney injury (AKI) in patients hospitalized with COVID-19 has been reported to be 37% [3] . Causes of SARS-CoV-2-induced AKI may vary. Hemodynamic factors like prerenal azotemia, the direct cytopathic effect of SARS-CoV-2 on the glomeruli and renal tubules, endothelial dysfunction leading to fibrinoid necrosis and microthro mb us development, the cytokine storm and vasculitis have been suggested as underlying reasons [5] [6] [7] . Renal involvement is common in AAV, and 75% of patients have renal involvement varying from asymptomatic alterations in kidney functions and urine abnormalities to rapidly progressing glomerulonephritis [8] . COVID-19 and AAV share similar common features, so it may be difficult to distinguish the etiology of AKI that occurs during or after COVID-19. IgA nephropathy is the most common primary glomerulonephritis worldwide and its clinical manifestations vary widely. However, asymptomatic hematuria and progressive loss of kidney function are common. In this case, renal biopsy showed crescent, but was not pauci-immune and the biopsy was compatible with IgA nephropathy; but immunofluorescence examination of this patient showed nonspecific deposition, and typical mesangial deposition was not present. In addition, there are a number of reports about patients with IgA nephropathy and seropositive ANCA. Yang et al. [9] demonstrated that ANCApositive IgA nephropathy patients had more severe clinical and histological characteristics than those with ANCA-negative, and their renal prognosis was relatively better with aggressive immunosuppressive therapy in the short term. Pulmonary involvement is very common in both AAV and COVID-19, and diagnosis can be diffic ult as they share common clinical and radiological features. In COVID-19, multifocal bilateral groundglass areas scattered peripherally and posteriorly and the resulting overlap of consolidations are considered as predominant radiological manifestation of the disease [10] . DAH represents a syndrome that can complicate many clinical conditions and may be life-threatening, requiring immed ia te treatment [11] . Conditions causing DAH can be clinically categorized as pulmonary-renal syndromes, vasculitides, autoimmune disease, and those secondary to drug action [11] . When consolidation and ground-glass opacities are diffuse, this usually represents DAH. Primary pulmona ry involvement due to DAH in AAV resembles nonspecific interstitial pneumonia or has a patchy ground-gla ss appearance, but involvement can sometimes be confusing [12] . Post-mortem examination of COVID-important to use serological tests and clinical data to differentiate COVID-19 infection from underlying autoimmune lung disease [14] . Some factors are involved in the pathogenesis of the AAV by triggering autoimmunity due to genetic factors, infectious agents, various specific drugs, environmental exposures, and other factors [15] . It has been reported that systemic viral and/or bacterial infections may trigger autoimmunity and cause AAV [15] . SARS-CoV-2 may trigger the presentation or exacerbation of autoimmune diseases [16, 17] and the mechanisms include molecular mimicry, viral persistence, epitope propagation, and formation of neutrophil extracellular traps (NETs) [18] . Patients with AAV also have high levels of circulating NETs, and NETs have been observed in kidney biopsy specimens from patients with AAV [19] . NETs contain proinflammatory proteins and are thought to contribute to the development of vasculitis directly by causing endothelial cell injury, and activating the complement system and indirectly by the production of PR3 and myeloperoxidase (MPO)-ANCA [20] . In addition, SARS-CoV-2 causes pulmonary endotheliitis leading to thrombotic microangiopathy, thrombosis, and hemorrhage, as shown in a recent autopsy study [21] . Clinical evidence of disease in at least two of the three locations (upper airways, lung, and kidney) and biopsy results demonstrating disease in at least one, preferably two, of these organ systems are the diagnostic criteria for AAV [22] [23] [24] . ANCAs are serologic markers of AAV and play an important role in the pathogenesis of various autoimmune diseases. ANCA antibodies help distinguish AAV from COVID-19. Cases of AAV have been reported after COVID-19 infection [25] [26] [27] . Pulmonar y hemorrhage with very high PR3-ANCA is very rare in IgA nephropathy. On the other hand, incidenta l mesangial IgA deposits are sometimes detected in the kidney biopsy specimens of renal transplant donors [28] .In this case, DAH, rapidly progressive kidney disease, and very high serum PR3-ANCA (>200RU/mL) support the diagnosis of AAV. Immunosuppression is the cornerstone of treatment for AAV associated pulmonary-renal syndrome. A multidisciplinary strategy is used to treat AAV, which typically comprises corticosteroids, rituximab, or cyclophosphamide [29] . IVIG is a biological product including polyclona l immunoglobulin G. IVIG has been shown to inhibit ANCA-induced neutrophil activation and cytokine release in vitro, and anti-idiotypic antibodies against ANCAs have been explored in IVIG preparations [30] . In addition, IVIG has been used successfully in AAV with relapsing and refractory disease [31] . In Wuhan, in a small case series of 3 patients who had deteriorated due to COVID-19, they showed clinical and radiographic improvement with the onset of IVIG [32] . Therefore, we used IVIG due to its successful results in COVID-19 disease [33] and AAV. Plasma exchange has been successfully used in AAV, SLE, and other autoimmune disorders [34] . In the study of Klemmer et al., 20 small-vessel vasculitis patients received intravenous immunosuppressive therapy and plasma exchange and the DAH showed 100% recovery with some improvement in renal function [34] . In the present case, the patient improved after pulse methylprednisolone, plasma exchange sessions and IVIG. The patient's renal function improved and DAH recovered completely. Due to the simultaneous COVID-19 infection, the use and timing of immunosuppressive therapy should have been chosen carefully in this life-threatening condition. In conclusion, early detection of AAV is important in cases with COVID-19 infection, and prompt diagnosis and appropriate management of AAV are essential to reduce morbidit y and mortality. This case highlights that SARS-CoV-2 could be the trigger for AAV and, and this should be kept in mind in such cases presented with pulmonary-renal manifestations. Two immunocompromised patients with diffuse alveolar hemorrhage as a complication of severe coronavirus disease 2019 Clinical manifestations of granulomatosis with polyangiitis: key considerations and major features Acute kidney injury in patients hospitalized with COVID-19 COVID-19 and granulomatosis with polyangiitis (GPA): a diagnostic challenge Multiorgan and renal tropism of SARS-CoV-2 Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans ANCA-associated vasculitis: core curriculum 2020 Clinical features of IgA nephropathy with serum ANCA positivity: a retrospective case-control study Radiologic diagnosis of patients with COVID-19 Diffuse pulmonar y hemorrhage: clues to the diagnosis Pulmonary manifestations of Wegener granulomatosis: CT findings in 57 patients and a review of the literature Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or vasculitis: radiologic presentation Vasculitides associated with infections, immunization, and antimicrob ia l drugs Coronavirus disease 2019 an emerging trigger for primary fibromyalgia syndrome: A tale of three cases post-COVID-19 C ould Sarscoronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment COVID-19-Associated Kidney Injury: A Case Series of Kidney Biopsy Findings Pulmonar y vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years 2012 revised internatio na l chapel hill consensus conference nomenclature of vasculitides The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis COVID-19-induced granulomatos is with polyangiitis ANCA-associated vasculitis after COVID-19 Microscopic polyangiit is associated with coronavirus disease-2019 (COVID-19) infection in an elderly male Significance of Glomerular Immune Reactivity in Time Zero Biopsies for Allograft Survival Beyond IgA Update on the treatment of granulomatosis with polyangiitis (Wegener's) Anti-idiotypes against anti-neutrop hil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis Intraveno us immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019 A single center experience of intravenous immunoglobulin treatment in Covid-19 Plasmapheres is therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis Figure 1: Chest computerized tomography (CT) showing (a) Lung window: Fused consolidation and infiltrations in the form of ground-glass opacity in both lungs, especially the left with septal thickening and air bronchograms suggestive of diffuse alveolar hemorrhage (DAH). (b) Mediastina l window Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.